Brent Goodman is a Neurology physician affiliated with HonorHealth. OpenAlex indexes 337 publications with 1,837 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7242 E Osborn Rd Ste 400
Scottsdale, AZ 852516494
Telephone
602-258-3354Provider last certified this registry record 7 Mar 2025.
Clinical trials
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
Sponsor: Chelsea Therapeutics
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year2025119 payments$172,114openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202419 payments$23,366openpaymentsdata.cms.gov ↗
- Pharming Healthcare, Inc.Program year20244 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
52.1%Cholinesterase Inhibitor52.1%Pyridostigmine Bromide100%Part D≥17 patientsCardiovascular
29.8%alpha-Adrenergic Agonist18.1%Midodrine Hcl100%Part D<11 patientsCentral alpha-2 Adrenergic Agonist11.7%Clonidine100%Part D<11 patientsRespiratory
18.1%Mast Cell Stabilizer18.1%Cromolyn Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review
Clinical Gastroenterology and Hepatology
2025 - Joint Hypermobility, Autonomic Dysfunction, Gastrointestinal Dysfunction, and Autoimmune Markers: Clinical Associations and Response to Intravenous Immunoglobulin Therapy
The American Journal of Gastroenterology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Tania Phillips, MD
HonorHealth
Erkut Borazanci, MD, MS
HonorHealth
Zain Khalpey, MD, MRCS
HonorHealth
Venkatesh Ramaiah, MD
HonorHealth
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”